| Literature DB >> 34959351 |
Pan Liang1,2, Linshen Mao1,2, Yanli Dong1,2, Zhenwen Zhao3, Qin Sun1,2, Maryam Mazhar1,2, Yining Ma1,2, Sijin Yang1,2, Wei Ren1,2.
Abstract
Liposomes are attractive carriers for targeted and controlled drug delivery receiving increasing attention in cancer photothermal therapy. However, the field of creating near-infrared nanomaterial-liposome hybrid nanocarriers (NIRN-Lips) is relatively little understood. The hybrid nanocarriers combine the dual superiority of nanomaterials and liposomes, with more stable particles, enhanced photoluminescence, higher tumor permeability, better tumor-targeted drug delivery, stimulus-responsive drug release, and thus exhibiting better anti-tumor efficacy. Herein, this review covers the liposomes supported various types of near-infrared nanomaterials, including gold-based nanomaterials, carbon-based nanomaterials, and semiconductor quantum dots. Specifically, the NIRN-Lips are described in terms of their feature, synthesis, and drug-release mechanism. The design considerations of NIRN-Lips are highlighted. Further, we briefly introduced the photothermal conversion mechanism of NIRNs and the cell death mechanism induced by photothermal therapy. Subsequently, we provided a brief conclusion of NIRNs-Lips applied in cancer photothermal therapy. Finally, we discussed a synopsis of associated challenges and future perspectives for the applications of NIRN-Lips in cancer photothermal therapy.Entities:
Keywords: hybrid nanocarriers; liposomes; near-infrared nanomaterials; photothermal therapy; targeted drug delivery
Year: 2021 PMID: 34959351 PMCID: PMC8704010 DOI: 10.3390/pharmaceutics13122070
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Schematic illustration of liposomes loading various NIRNs for cancer PTT.
Figure 2(A). (i) Photoluminescence intensity (PL) spectra of CDs, blank liposomes, CDs liposomes, and CDs + CB liposomes at excitation of 500 nm. (ii) (a–c) In vivo PL images of nude mice treated with intratumor injection of CDs (the left) and CDs + CB liposomes (the right) 0.25 h, 1 h, and 2 h post injection, respectively; (d) ex vivo images of mice tissues 24 h post tail intravenous injection of CDs (the left) and CDs + CB liposomes (the right). The color bars represent the PL intensity. Reprinted with permission from [58], Elsevier, 2018. (B) Measurement of photothermal property and photostability of rGO@AuNS-Lipid. (i) Temperature changes (ΔT) of the solution containing 60 µg/mL rGO@AuNS-Lipid irradiated at various laser power densities. (ii) Temperature change of the solution containing different concentrations of rGO@AuNS-Lipid irradiated at a laser power density of 0.3 W/cm2. (iii) Thermal stability of rGO@AuNS-Lipid (continuous six cycles of laser on/off) under 808 nm laser of 0.3 W/cm2. (iv) Infrared thermographic images recorded with a thermal infrared camera of rGO@AuNS-Lipid in 96-well plate irradiated by 808 nm laser at a power intensity of 0.1 W/cm2. Reprinted with permission from [37], John Wiley and Sons, 2020.
Figure 3Three strategies developed for NIRNs attaching to liposomes.
Different NIRN-Lips in terms of preparation method, encapsulation strategy, type of NIRNs and lipid composition.
| Preparation Method | Encapsulation Strategy | Type of NIRNs | Lipid Composition | Drug Load | Average Diameter (nm) | Zeta Potential (mV) | Ref. |
|---|---|---|---|---|---|---|---|
| Thin-film hydration | Within the lipid bilayer | CNHs | DMPC, DSPC, Chol | / | 80.0–100.0 | / | [ |
| Within the lipid bilayer | CDs | DPHHP, DSHHP, Chol | CUR | 128.0 | 29.9 | [ | |
| Within the lipid bilayer | AuNPs | SPC, Chol | PTX | 281.1 | 45.3 | [ | |
| Within the lipid bilayer | QDs | EPC, Chol, DSPE-PEG2000 | CGT | 100.0 | −17.1 | [ | |
| Within the lipid bilayer | QDs | PC, Chol, DSPE-PEG2000 | APO | 142.0 | 50.3 | [ | |
| Within the lipid bilayer | QDs | Chol, DSPE-PEG2000 | siRNA | 171.7 | −2.7 | [ | |
| within the lipid bilayer | QDs | PC, Chol, PEG-6000 | / | 270.0 | / | [ | |
| Within the lipid bilayer | QDs | DPPC, DC-Chol, DSPE-PEG2000 | / | 89.7 | 20.1 | [ | |
| Within the lipid bilayer | QDs | L-α-lysolecithin, Chol | DOX | 105.6 | 0.5 | [ | |
| Within the lipid bilayer | GO, CDs | DPPC, Brij 78, Chol | DOX | 129.6 | −7.3 | [ | |
| On the outer surface | AuNPs | SPC, Chol | DOX | 100.0 | −14.7 | [ | |
| On the outer surface | AuNRs | DOTAP, DOPE, Chol | NIR-797 | 89.0 | 46.4 | [ | |
| Encapsulated into the aqueous core | CDs | DSPE-mPEG2000, EPG, SPC, Chol | DOX | 87.4 | −12.9 | [ | |
| Encapsulated into the aqueous core | CDs | SPC, Chol, cephalin | / | 80.0 | −15.4 | [ | |
| Encapsulated into the aqueous core | CDs | DSPE-mPEG2000, | DOX | 108.9 | −31.4 | [ | |
| Encapsulated into the aqueous core | CDs | DSPE-mPEG2000, DPPC, Chol | CB | 60.0–80.0 | −2.6 | [ | |
| Encapsulated into the aqueous core | GO | SPC | DOX | 391.3 | / | [ | |
| Encapsulated into the aqueous core | GNs | DPPC, Chol, DSPE-mPEG2000 | DOX | 141.0 | −1.3 | [ | |
| Encapsulated into the aqueous core | AuNSs | P90G, Chol | calcein | 170.0 | −70 | [ | |
| Encapsulated into the aqueous core | AuNSs | DPPC, MSPC, DSPE-PEG-SH, Chol | PTX | 293.9 | 2.5 | [ | |
| Encapsulated into the aqueous core | GQDs, AuNPs | DSPC, Chol | DOX | 167.0 | 13.0 | [ | |
| Encapsulated into the aqueous core | AuNPs | EYPC, DSPE-PEG2000 | VCR | 113.4 | −11.3 | [ | |
| Encapsulated into the aqueous core | AuNPs | SPC, Chol | TMZ | 89.0 | −69 | [ | |
| Encapsulated into the aqueous core | AuNPs | DSPE-PEG2000, DPPC | DOX | 196.8 | −29.5 | [ | |
| Encapsulated into the aqueous core | AuNPs | SPC, Chol, PEG2000 | DOX | 182.2 | / | [ | |
| Encapsulated into the aqueous core | AuNPs | DOPC, DOTAP, DSPE-PEG2000 | VP | 170.0 | 45.0 | [ | |
| Encapsulated into the aqueous core | AuNRs | SPC, HSPC, DSPE-PEG2000 | DOC | 163.1 | −32.8 | [ | |
| Encapsulated into the aqueous core | QDs | DPPC, DSPG, DSPE-PEG2000 | PTX | 102.5 | −19.8 | [ | |
| Encapsulated into the aqueous core | QDs | DSPC, DOTAP, Chol | / | 114.0 | 24.8 | [ | |
| Encapsulated into the aqueous core | QDs | DOPC, DOPE | / | 103.0 | −13.2 | [ | |
| Encapsulated into the aqueous core/within the lipid layer | AuNPs | SPC, Chol, DSPE-PEG2000 | PTX | 149.2 | −2.5 | [ | |
| Encapsulated into the aqueous core/within the lipid layer | AuNPs | DPPC | / | 160.0 | −6.2 | [ | |
| Encapsulated into the aqueous core/on the outer surface | AuNPs | DPPC, HSPC, EPC, | DOX | 154.8 | −38.0 | [ | |
| Encapsulated into the aqueous core/on the outer surface | AuNPs | DPPC, MPPC, DSPE-PEG2000 | Calcein | 118.0–146.0 | −9.6 | [ | |
| Encapsulated into the aqueous core/on the outer surface | QDs | DSPC, DOTAP, DSPE-PEG2000 | / | 107.4 | −0.8 | [ | |
| Encapsulated into the aqueous core/on the outer surface | QDs | DOPE, DSPC, Chol, DSPE-PEG2000 | / | 100.0 | 0 | [ | |
| On the outer surface | AuNPs | DPPC, HSPC, DSPE-PEG2000, Chol | CTD | 96.4 | 28.7 | [ | |
| On the outer surface | GNS | SPC, Chol | RES | 141.7 | 22.7 | [ | |
| On the outer surface | AuNPs | HSPC | CUR | 100.0 | 22.0 | [ | |
| On the outer surface | AuNPs | DSPC, Chol | / | 200.0 | / | [ | |
| On the outer surface | AuNPs | DSPC, Chol | QUE | 120.0 | 11.8 | [ | |
| On the outer surface | AuNPs | SPC, CS | OA | 172.0 | 22.7 | [ | |
| On the outer surface | AuNPs | SPC, Chol | BA | 149.4 | / | [ | |
| On the outer surface | AuNPs | SPC | CUR | 100.0–120.0 | / | [ | |
| Solvent injection | encapsulated into the aqueous core | AuNPs | EPC, TPGS-COOH, Chol | DOC | 217.1 | −14.5 | [ |
| Encapsulated into the aqueous core | AuNPs | EPC, DOPG | / | 140.0–150.0 | / | [ | |
| Ultrasonication | On the outer surface/encapsulated into the aqueous core | CDs | DSPC, Chol | / | 230.0 | 20.0 | [ |
| Within the lipid bilayer | GO | POPC | / | 238.0 | −15.2 | [ | |
| Within the lipid bilayer | GO | FA-PEG-DSPE, biotin-PEG-DSPE, DMPG | RES | 148.0 | −23.6 | [ | |
| Encapsulated into the aqueous core | AuNCs | DOPC, DSPE-PEG2000, Chol | TRP2 | 64.5 | −10.0 | [ | |
| Hydrothermal method | On the outer surface | CDs | triolein | / | 103.0 | / | [ |
| Covalent attachment | On the outer surface | CNTs | SPC, DSPE-PEG2000, Chol | Oridonin | / | / | [ |
| On the outer surface | CNTs | biotin-PEG2000-PL, HSPC, PE | Calcein | 10.0 | −16.3 | [ | |
| Ionic interaction assembly method | On the outer surface | GO | DPPC, Brij 78, DOTAP, Chol | DOX | 153.9 | −32.6 | [ |
| Plasmon resonance coating method | On the outer surface | AuCLs | DPPC, MPPC, DSPE-PEG2000 | DOX | 171.5 | −1.0 | [ |
| Extrusion method | Encapsulated into the aqueous core | GNC | DOPC, N-dod-PE | / | 175.0 | −37.7 | [ |
| Within the lipid bilayer | QDs | L-α-lysolecithin, Chol, PEG-Chol, DOPE | BP | 104.2 | −11.3 | [ |
Figure 4(A). (i) Schematic illustration of the preparation process of WS2QDs-Van@lipo. (ii) Cryo-electron microscopy images of WS2QDs-Van@lipo. Scale bar: 50 nm. (iii) Elemental mapping images (O in blue, S in purple) of the WS2QDs-Van@lipo obtained with TEM. Scale bar: 100 nm. Reprinted with permission from [95], American Chemical Society, 2020. (B) Illustration of dual-targeting GTSL-CYC-HER2 and its intracellular trafficking pathway in tumor cells. Reprinted with permission from [35], Springer Nature, 2021.
Surface modified NIRN-Lips target to different tumor cells.
| Type of NIRN-Lips | Drug Load | Surface Modification | Targeted Tumor Cells | Surface Engineering Techniques Used | Characterization | Ref. |
|---|---|---|---|---|---|---|
| FA-MWNTs-Lips | Oridonin | FA | HepG2 cells | FA-conjugated chitosan attached onto MWNTs-COOH using a non-covalent bond method; liposome containing oridonin covalently attached to MWNTs-COOH to form MWNTs-Lips. | FTIR, DLS, TEM, TGA | [ |
| FA-CDs-Lips | / | FA | 4T1 cells | Terminal amino functional group of CDs-Lips reacted with the carboxyl groups of FA. | DLS, TEM, FTIR | [ |
| FA-GQDs/AuNPs-Lips | DOX | FA | 4T1 cells | PEGylated FA (1 mg/mL) as targeting ligand was attached on the surface of AuNPs/QODs-Lips (5 mg/mL) through incubation process at room temperature. | FTIR, DLS, TEM, AFM, EDAX, X-ray, CT | [ |
| FL/QDs-TK | / | FA | BEL-7402, Hep3B and SMMC-7721 cells | DSPE-PEG2000-folate were modified on liposomes by thin film hydration method. | DLS, TEM, FESEM, UV-vis, Bio-Rad imaging system | [ |
| FA-DOX@CDs-Lips | DOX | FA | 4T1 cells | DSPE-MPEG2000-FA was noncovalently inserted into the lipid bilayer. | DLS, FTIR, TEM, XPS, 1HNMR spectra | [ |
| FA-PEG-Lip@rGO/RES | RES | FA, PEG | A549 and MCF-7 cells | 0.1 μmol FA-PEG-DSPE was added to stabilize and modify liposome system. | DLS, TEM, AFM | [ |
| CPP-CDs-Lips | CUR | CPP | MCF-7 cells | Carboxylic groups of CPP reacted with cholesterol to form conjugate. | DLS, TEM, FTIR | [ |
| Man-CDs-Lips | / | D-mannose | HepG2 cells | D-mannose was non-covalently attached to the liposome surface. | TEM, AFM, XRD | [ |
| SPACE-AuNSs-Lips | Calcein | SPACE peptides | NIH-3T3 cells | 5 mg/mL POPE-NHS and 5 mg/mL SPACE peptide (pH = 8) were added into the mixture following a 2 h preincubation at room temperature. | DLS, TEM, DSC | [ |
| DOC-AuGSH-TPGS-Tf | DOC | TPGS, Tf | glioma cells | TPGS-COOH on the liposome surface were activated and then incubated with 1 mL Tf solution (10 mg/mL) at room temperature for 30 min and kept overnight at 4 °C. | DLS, TEM, AFM, NMR | [ |
| TPP-Lips-VP-10AuNPs | VP | TPP | mitochondria of HCT116 cells | DSPE-PEG2000-NH2 were inserted into the pre-formed liposomes, and then the PEGylated and TPP-coupled liposomes were prepared by the EDC-NHS coupling method. | DLS, TEM, spectrophotometer | [ |
| Aptamo-QDs-Lips | siRNA | Anti-EGFR aptamer | MDA-MB-231 cells | DSPE-mPEG2000-aptamer were added to the prepared QDs-Lips and incubated for 4 h at 37 °C | DLS, TEM | [ |
| Biotin-QDs-Lips | / | Biotin | A431 cells | Biotin-DSPE (0.012 μmol/mL) were added to prepare liposomes. | DLS, TEM, spectrofluorometer | [ |
Note: the full names of NIRN-Lips in Table 2 can be found in Abbreviations.
Figure 5NIR light-triggered drug release mechanism of NIRN-Lips.
Brief summary of the recently developed NIRN-Lips for cancer PTT.
| Type of NIRN-Lips | NIR Laser | Temperature Reached | Drug Load | Antitumor Mechanism | Cancer Treated | Ref. |
|---|---|---|---|---|---|---|
| GNS-BA-Lips | 808 nm | 43 °C in 10 min | BA | (1) Local heat generated from NIR light cause PTT; (2) enhance intracellular BA accumulation | Cervical cancer | [ |
| CDs-CB-Lips | 500 nm | / | CB | (1) Increase cytotoxicity and cellular uptake of CB | Breast cancer | [ |
| CTD-TSL@GNS | 808 nm | 44 °C in 20 min | CTD | (1) Block the heat shock response and inhibit the expression of HSP70 and BAG3, thus enhance therapeutic effect of CTD | Cervical cancer | [ |
| Au Lips Cur NPs | 780 nm | 50 °C in 5 min | CUR | (1) Exert cytotoxic effect; inhibit cell proliferation and migration; (2) NIR light irradiation on Au Lips Cur NPs trigger the release of CUR | Melanoma | [ |
| CDs-DOX/ICG-Lips | 808 nm | 56.8 °C in 5 min | DOX | (1) Induce cell apoptosis; (2) inhibit cell proliferation; (3) generate heat to kill cells | Liver cancer | [ |
| FA-DOX@CDs-Lips | 480 nm | / | DOX | (1) Induce cell apoptosis; (2) increase cytotoxicity and intracellular uptake of DOX | Breast cancer | [ |
| HMNS/SiO2/GQD-DOX-Lips | 808 nm | 56.8 °C in 20 min | DOX | (1) Induce ROS generation and heat produced by NIR irradiation to kill cells | Esophagus cancer | [ |
| FA-GQDs/AuNPs-Lips | 750 nm | 55 °C in10 min | DOX | (1) Generate ROS and heat to kill cells; (2) Increase cytotoxicity; (3) generate heat to kill cells | Breast cancer | [ |
| GNPs and DOX-TSL; HGNPs and DOX-TSL | 808 nm | 45 °C in 5 min | DOX | (1) Increase cytotoxicity and cellular uptake of DOX; (2) transfer NIR light to heat | Breast cancer | [ |
| DOX and HAuNS-TSL | 808 nm | 49.9 °C in 5 min | DOX | (1) Enhance cytotoxicity; increase intracellular DOX concentration | Liver cancer | [ |
| DOX/AuCLs-TSL | 808 nm | / | DOX | (1) AuCLs on the TSL absorb the NIR light to cause membrane destabilization; (2) increase cell cytotoxicity | Triple-negative breast cancer | [ |
| AuNRs/DOCL-R | 748 nm | 60 °C in 10 min | DOC | (1) Enhance intracellular entrance; (2) increase DOC accumulation in tumor site; (3) induce ROS generation | Prostate cancer | [ |
| QE-LipoAu | 750 nm | 48 °C in 7 min | QE | (1) After PTT, increase photothermal cytotoxicity, induce cell apoptosis; (2) depolymerize microtubules, suppress HSP70 expression, and cause DNA damage | Hepatocellular carcinoma | [ |
| GNS-CS-OA-Lips | 808 nm | / | OA | (1) After NIR light irradiation, a local temperature increase caused by AuNPs to kill cells; (2) hyperthermia promotes phase conversion from gel-to-liquid crystalline of cells membrane, and dramatically enhances intracellular uptake of OA, leading to the tumor cells apoptosis. | Osteosarcoma | [ |
| FA-PEG-Lip@rGO/RES | 780 nm | 59.6 °C in 5 min | RES | (1) Enhance cellular uptake of RES; protect stability of resveratrol; (2) generate heat to kill cells | Breast cancer | [ |
| GNS@CTS@RES-Lips | 808 nm | 66 °C in 10 min | RES | (1) Convert NIR light to heat to enhance the release and intracellular accumulation of RES | Cervical cancer | [ |
| FA-CDs-Lips | 808 nm | 57–62 °C in 5 min | / | (1) Induce ROS generation; (2) increase cellular uptake | Breast cancer | [ |
Note: the full names of NIRN-Lips in Table 3 can be found in Abbreviations.
Figure 6The recently fabricated NIRN-Lips for PTT of different types of cancer. Reprinted with permission from [9], John Wiley and Sons, 2016; [58], Elsevier, 2019; [67], Royal Society of Chemistry, 2019; [88], Dove Medical Press, 2018; [107] Royal Society of Chemistry, 2017; [118], Informa Healthcare, 2018; [119], Springer Nature, 2020; [120], Ivyspring International Publisher, 2016; [122], Springer Nature, 2020; [125], Royal Society of Chemistry, 2018; [141], Royal Society of Chemistry, 2017.
Figure 7(A) Schematic diagram of the Temperature-Sensitive CNT-PS/siRNA Nanoparticle for Synergistic PTT and GT for Cancer Cells. Reprinted with permission from [36], American Chemical Society, 2021. (B) Schematic overview of the rGADA synthesis, and the rGADA/KrasI complexes used in gene/PTT synergistic therapy and photoacoustic/photothermal dual-modal imaging in pancreatic cancer. Reprinted with permission from [37], John Wiley and Sons, 2020.